Optometrists good partners for combination with cataract surgery

Article

ECP is a safe and effective IOP-lowering procedure that can be performed as a stand-alone intervention, but is especially useful for patients who are already undergoing cataract surgery.

Boston-Endocyclophotocoagulation (ECP) is a safe and effective IOP-lowering procedure that can be performed as a stand-alone intervention, but is especially useful for patients who are already undergoing cataract surgery, said Leonid Skorin, Jr., OD, DO, MS, at the annual meeting of the American Academy of Optometry.

"Performing ECP in combination with cataract surgery is simple for the surgeon and the patient," said Dr. Skorin, senior staff ophthalmologist, Mayo Clinic Health System, Albert Lea, MN.

The procedure adds only about 5 minutes to the OR time, and it does not increase the risk of postoperative morbidity, Dr. Skorin said. "The recovery process after combination ECP-phacoemulsification is roughly the same as after the cataract procedure alone, so glaucoma patients can derive the IOP-lowering benefit of the ECP procedure without any added burden," he said.

"Furthermore, since ECP is performed through the cataract incision and spares conjunctival tissue, it does not preclude trabeculectomy or another type of glaucoma surgery at a later time should it become indicated," he added.

When performing combination ECP-phacoemulsification, Dr. Skorin first removes the cataract and implants the IOL, easing the access to the ciliary processes. Then, he instills intracameral non-preserved lidocaine under the edge of the iris to improve treatment tolerability. He usually aims to treat at least 270 degrees of the ciliary processes. The treatment endpoint is contracture and whitening.

Postoperative outcomes

"I am aware of only a single reported case of hypotony following aggressive ECP in an adult, but the eye involved had previous surgery," he said. "I have treated nearly 360 degrees of the ciliary processes without any untoward effects."

He added that although the aim of this treatment is to ablate the ciliary processes and the space between them, the latter valleys are less accessible from an anatomic standpoint. This means the entire ciliary epithelium will not be fully treated. Consequently, some residual aqueous production will occur, even when attempting nearly 360 degrees of treatment.

Because the laser in ECP is used to precisely target the ciliary processes, collateral tissue evades damage. The additional laser application does increase the risk of greater inflammation postoperatively, so Dr. Skorin increases the dosing of anti-inflammatory corticosteroid drops to every 2 hours for the first week instead of Q.I.D. Patients can start to titrate glaucoma medications 6 to 8 weeks after surgery.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.